Bullous pemphigoid is an autoimmune skin disorder characterized by large, fluid-filled blisters and vesicles on normal looking skin or erythematous skin. It mainly affects the elderly population above 60 years of age. The bullous stem from beneath the epidermal-dermal junction. Bullous pemphigoid is treated using systemic corticosteroids like prednisone combined with immunosuppressants like azathioprine. Topical corticosteroids are used for localized blisters.
The bullous pemphigoid market is estimated to be valued at USD 1.4 Bn in 2024 and is expected to reach USD 2.8 Bn by 2031, growing at a compound annual growth rate (CAGR) of 10.2% from 2024 to 2031.
The current geopolitical uncertainties are impacting the growth of the Bullous Pemphigoid Market. The ongoing military conflicts and economic sanctions imposed between major countries are disrupting global supply chains and manufacturing industries. This is hampering the consistent supply of raw materials required for producing drugs to treat bullous pemphigoid. It is also affecting the cross-border trade and exports of these drugs from major manufacturing hubs to other regions witnessing high disease prevalence.
Get More Insights on- Bullous Pemphigoid Market
Get This Report in Japanese Language: 水疱性類天疱瘡市場
Get This Report in Korean Language: 수포성 천포창 시장
English
Arabic
Français
Español
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian